Literature DB >> 3730458

The effect of serum dexamethasone concentrations in the dexamethasone suppression test.

V Carr, H Morris, J Gilliland.   

Abstract

Serum dexamethasone and cortisol concentrations were measured in a sample of 98 psychiatric inpatients during the course of the 1-mg oral overnight Dexamethasone Suppression Test (DST). Suppressors were found to have significantly higher serum dexamethasone concentrations than nonsuppressors at each time of sampling (8:00 AM, 4:00 PM, and 11:00 PM). There was a significant inverse curvilinear relationship between serum dexamethasone and cortisol concentrations at each sample time. Although serum dexamethasone concentration was a potent determinant of postdexamethasone serum cortisol concentration, there were still significantly higher serum concentrations of cortisol in patients with major depression compared with patients with other disorders when dexamethasone concentrations were statistically controlled. By taking serum dexamethasone concentrations into account in defining DST suppression status, a modest increase in diagnostic specificity was achieved, but no substantial change in sensitivity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3730458     DOI: 10.1016/0006-3223(86)90238-6

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  3 in total

Review 1.  Pharmacoendocrinology of major depression.

Authors:  R T Rubin
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

2.  Judgement of the hypothalamic-pituitary-adrenocortical function in psychiatric patients by betamethasone-induced cortisol suppressibility.

Authors:  S Kasper; P Vecsei; P Richter; D Haack; K Diebold; L Katzinski
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

3.  Association between posttest dexamethasone and cortisol concentrations in the 1 mg overnight dexamethasone suppression test.

Authors:  Bjørn O Asvold; Valdemar Grill; Ketil Thorstensen; Marit R Bjørgaas
Journal:  Endocr Connect       Date:  2012-08-30       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.